Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3325 PK/PD in Hemodialysis Patients
NCT02510274Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP3325 in hyperphosphatemia (3 arms), sponsored by Astellas Pharma. Primary endpoints: Safety assessed by adverse events, Safety assessed by vital signs and 2 more. Started May 2014; status: completed.
02
Drugs
ASP3325
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02510274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510274.